Genetic disparity between potential hosts and donors limits the utilization and outcome allogeneic BMT by adversely affecting donor availability, engrafument, GVHD, and immune reconstitution. While both non-specific immunosuppression and T cell depletion can decrease frequency and severity of GVHD, no successful program of haploidentical or significantly mismatched unrelated donor BMT has emerged. Further, the non-specific immunologic manipulations and aggressive peri-BMT preparative regimens comprising present methodologies used to ameliorate GVHD are fraught with toxicities including end organ failure, increase in opportunistic infections, B-cell lymphoproliferative disease and loss of graft versus tumor effect. Therefore, attempts to inhibit allorecognitiion specifically while leaving intact the remaining immune repertoire would decrease non-specific toxicity while preserving or improving upon current standards of GVHD control. The central goal of this project is to attempt to selectively inactivate only the small numbers of allospecific T cells transferred in the donor BM that are responsible for GVHD. Alloreactive T cells require two signals for activation. One signal is delivered by alloAg via the TCR and the other by costimulatory molecules. Blockade of B7 family mediated costimulation can induce anergy to fully mismatched allogeneic donor T cells ex vivo. Based on these findings, we have commenced a clinical trial of ex vivo tolerance induction of donor T cells to alloAg. If long-lasting and irreversible unresponsiveness to alloAg can be induced, the associated attendant clinical toxicities of GVHD would be ameliorated while the eligible donor pool would be increased without sacrificing immunity to infectious agents and tumor. To achieve these goals, Four Aims are proposed. First, to continue our ongoing clinical trials of ex vivo anergization of donor T cells to alloAg. Second, block additional pathways to optimize alloAg specific anergy. Third, compare sources of allogeneic T cells to study naive vs previously activated T cells and determine their capacity to be anergized to alloAg. Fourth, determine whether alloanergization results in retention of normal T cell function against pathogens and tumor cells. This Project relies upon and is highly interdependent with the second project (for selection of costimulatory pathways that might block CD4 and CD8 T cell anergy) and with the third project (for preclinical animal models determining costimulatory pathways and study of naive vs previously activated T cells).

Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Tapper, Elliot B; Finkelstein, Daniel; Mittleman, Murray A et al. (2016) A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis. Clin Gastroenterol Hepatol 14:753-9
Davies, Jeff K; Gribben, John G; Brennan, Lisa L et al. (2008) Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood 112:2232-41
Lafuente, Esther M; van Puijenbroek, Andre A F L; Krause, Matthias et al. (2004) RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. Dev Cell 7:585-95
Brown, Julia A; Dorfman, David M; Ma, Feng-Rong et al. (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170:1257-66
Molrine, Deborah C; Antin, Joseph H; Guinan, Eva C et al. (2003) Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 101:831-6
Rodig, Nancy; Ryan, Timothy; Allen, Jessica A et al. (2003) Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 33:3117-26
Hirano, Naoto; Butler, Marcus O; Von Bergwelt-Baildon, Michael S et al. (2003) Autoantibodies frequently detected in patients with aplastic anemia. Blood 102:4567-75
Tzachanis, Dimitrios; Appleman, Leonard J; Van Puijenbroek, Andre A F L et al. (2003) Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification. J Immunol 171:1691-6
Baecher-Allan, Clare; Brown, Julia A; Freeman, Gordon J et al. (2003) CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp 252:67-88; discussion 88-91, 106-14
Appleman, Leonard J; Tzachanis, Dimitrios; Grader-Beck, Thomas et al. (2002) Induction of immunologic tolerance for allogeneic hematopoietic cell transplantation. Leuk Lymphoma 43:1159-67

Showing the most recent 10 out of 31 publications